These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31163185)

  • 1. Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.
    D'Cunha RR; Murry DJ; An G
    J Pharm Sci; 2019 Oct; 108(10):3434-3442. PubMed ID: 31163185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
    Bae S; D'Cunha R; Shao J; An G
    Eur J Pharm Sci; 2018 May; 117():27-34. PubMed ID: 29425861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
    Ganguly S; Panetta JC; Roberts JK; Schuetz EG
    Drug Metab Dispos; 2018 Jul; 46(7):1014-1022. PubMed ID: 29674491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
    van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2017 Jun; 120():43-50. PubMed ID: 28288939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Oct; 436(1-2):127-34. PubMed ID: 22688250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
    Ito F; Miura M; Fujioka Y; Abumiya M; Kobayashi T; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N
    Int J Hematol; 2021 Jan; 113(1):100-105. PubMed ID: 33025461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
    Harmsen S; Meijerman I; Maas-Bakker RF; Beijnen JH; Schellens JH
    Eur J Pharm Sci; 2013 Mar; 48(4-5):644-9. PubMed ID: 23277288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
    Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
    Guo A; Marinaro W; Hu P; Sinko PJ
    Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.
    Eadie LN; Dang P; Goyne JM; Hughes TP; White DL
    PLoS One; 2018; 13(1):e0192180. PubMed ID: 29385210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
    Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors.
    Haouala A; Rumpold H; Untergasser G; Buclin T; Ris HB; Widmer N; Decosterd LA
    Drug Metab Lett; 2010 Apr; 4(2):114-9. PubMed ID: 20446917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.